Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 6/20 | 0.57 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.62 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | PDE6D | O43924 | 1/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19474869 | 1.00 | ABCC3 (0.62) | ABCC3ABCC4HMGCRALDH1A1CYP3A4 | |
| SCHEMBL4538040 | 0.99 | ABCC3 (0.62) | ABCC3ABCC4HMGCRALDH1A1CYP3A4 | |
| Zinc Ion SCHEMBL3884322 | 0.97 | ABCC3 (0.60) | ABCC3ABCC4HMGCRALDH1A1CYP3A4 | |
| SCHEMBL4538441 | 0.92 | HMGCR (0.61) | ABCC3ABCC4HMGCRALDH1A1CYP3A4 | |
| SCHEMBL3887767 | 0.91 | HMGCR (0.59) | ABCC3ABCC4HMGCRALDH1A1CYP3A4 | |
| SCHEMBL3305 | 0.90 | ABCC3 (0.57) | ABCC3ABCC4HMGCRALDH1A1CYP3A4 | |
| SCHEMBL16401134 | 0.86 | ABCC3 (0.53) | ABCC3ABCC4HMGCRALDH1A1CYP3A4 | |
| SCHEMBL17635504 | 0.85 | HMGCR (0.67) | ABCC3ABCC4HMGCRALDH1A1CYP3A4 | |
| SCHEMBL3885922 | 0.83 | HMGCR (0.62) | ABCC3ABCC4HMGCRALDH1A1CYP3A4 | |
| SCHEMBL1739610 | 0.83 | ABCC3 (0.43) | ABCC3ABCC4HMGCRALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3022213-B1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM AND PREPARATION OF ITS NOVEL INTERMEDIATES | SUVEN LIFE SCIENCES LTD (IN) | 2017-06-21 | — | — | EP | claimed |
| US-9518028-B2 | Process for the preparation of Rosuvastatin calcium and preparation of its novel intermediates | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-12-13 | — | — | US | claimed |
| US-20160304468-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM AND PREPARATION OF ITS NOVEL INTERMEDIATES | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-10-20 | — | — | US | claimed |
| EP-3022213-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM AND PREPARATION OF ITS NOVEL INTERMEDIATES | Suven Life Sciences Limited (IN) | 2016-05-25 | — | — | EP | claimed |
| WO-2015008294-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM AND PREPARATION OF ITS NOVEL INTERMEDIATES | SUVEN LIFE SCIENCES LIMITED (IN) | 2015-01-22 | — | — | WO | claimed |
| EP-3022213-B1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM AND PREPARATION OF ITS NOVEL INTERMEDIATES | SUVEN LIFE SCIENCES LTD (IN) | 2017-06-21 | — | — | EP | disclosed |
| US-9518028-B2 | Process for the preparation of Rosuvastatin calcium and preparation of its novel intermediates | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-12-13 | — | — | US | disclosed |
| US-9518028-B2 | Process for the preparation of Rosuvastatin calcium and preparation of its novel intermediates | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-12-13 | — | — | US | disclosed |
| US-20160304468-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM AND PREPARATION OF ITS NOVEL INTERMEDIATES | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-20160304468-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM AND PREPARATION OF ITS NOVEL INTERMEDIATES | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| EP-3022213-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM AND PREPARATION OF ITS NOVEL INTERMEDIATES | Suven Life Sciences Limited (IN) | 2016-05-25 | — | — | EP | disclosed |
| EP-3022213-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM AND PREPARATION OF ITS NOVEL INTERMEDIATES | Suven Life Sciences Limited (IN) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015008294-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM AND PREPARATION OF ITS NOVEL INTERMEDIATES | SUVEN LIFE SCIENCES LIMITED (IN) | 2015-01-22 | — | — | WO | disclosed |
| WO-2015008294-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM AND PREPARATION OF ITS NOVEL INTERMEDIATES | SUVEN LIFE SCIENCES LIMITED (IN) | 2015-01-22 | — | — | WO | disclosed |
| WO-2009128091-A2 | CRYSTALLINE FORM OF(7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-(N- METHYL-N-METHYLSULFONYLAMINO)PYRIMIDIN-5-YL]-(3R,5S)- DIHYDROXY-(E)-6-HEPTENOIC ACID INTERMEDIATE, PROCESS FOR PREPARING THE SAME AND USE THEREOF | MATRIX LABORATORIES LIMITED (IN) | 2009-10-22 | — | — | WO | disclosed |
| US-20090076292-A1 | Rosuvastatin intermediates and process for the preparation of rosuvastatin | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304468-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM AND PREPARATION OF ITS NOVEL INTERMEDIATES | ORAI1, RYR1, CACNA1E | HMGCR 4/4885ABCC3 2911/4885ABCC4 2405/4885 |
| US-20090076292-A1 | Rosuvastatin intermediates and process for the preparation of rosuvastatin | HMGCR, PCSK9, CYP4A11 | HMGCR 1/4885ABCC3 2626/4885ABCC4 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.